Lukas Scheibler

Lukas Scheibler

Executive Vice President, Research and Development at Acucela Inc.

Update Profile
Location:
1301 Second Avenue Suite 1900, Seattle, Washington, United States
Company:
Acucela Inc.
HQ Phone:
(206) 805-8300

General Information

Experience

Department  - Alliances

Novartis AG

Education

Master's degree  - chemistry , University of Basel

Ph.D.  - chemistry , University of Lausanne , Switzerland

Affiliations

Board Member  - The National Bureau of Asian Research

Vice President of Ideation and Technology  - Alcon , Inc.

Recent News  

Lukas Scheibler, PhD
Executive Scientific Advisor Dr. Scheibler joined Acucela in August 2015 after a 13-year career in research and development, business development and clinical trial management at Novartis. Dr. Scheibler had worked since 2008 at Alcon, a division of Novartis. He most recently was a Vice President in charge of Alcon's Ideation and Technology Evaluation Center, the company's center of excellence in charge of identifying novel technologies that address unmet needs in ophthalmology. Before that, he served as Alcon's Vice President and Global Head of Clinical Trial Management. Dr. Scheibler started work at Novartis headquarters in Switzerland in 2002 as Manager of Global Drug Regulatory Affairs. While he served as VP and Global Head of R&D Alliances at Alcon from 2008 to 2011, the company made several major acquisitions and deals, including the purchase of LenSx Lasers for up to US $744 million, ESBATech for up to US $589 million and a Research Agreement with AstraZeneca for exclusive access to the company's ophthalmology compound library. Dr. Scheibler received a Master's degree in chemistry from University of Basel, Switzerland; a Ph.D. in chemistry from University of Lausanne, Switzerland; and his Postdoctoral Training from Harvard Medical School.

Read More

Lukas Scheibler, Ph.D., EVP, Research and Development

Read More

Lukas Scheibler, PhD
Executive Vice President, R&D Dr. Scheibler joined Acucela in August 2015 after a 13-year career in research and development, business development and clinical trial management at Novartis. Dr. Scheibler had worked since 2008 at Alcon, a division of Novartis. He most recently was a Vice President in charge of Alcon's Ideation and Technology Evaluation Center, the company's center of excellence in charge of identifying novel technologies that address unmet needs in ophthalmology. Before that, he served as Alcon's Vice President and Global Head of Clinical Trial Management. Dr. Scheibler started work at Novartis headquarters in Switzerland in 2002 as Manager of Global Drug Regulatory Affairs. While he served as VP and Global Head of R&D Alliances at Alcon from 2008 to 2011, the company made several major acquisitions and deals, including the purchase of LenSx Lasers for up to US $744 million, ESBATech for up to US $589 million and a Research Agreement with AstraZeneca for exclusive access to the company's ophthalmology compound library. Dr. Scheibler received a Master's degree in chemistry from University of Basel, Switzerland; a Ph.D. in chemistry from University of Lausanne, Switzerland; and his Postdoctoral Training from Harvard Medical School.

Read More

Browse ZoomInfo’s Directories